TITLE

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

AUTHOR(S)
Bertino, Pietro; Porta, Camillo; Barbone, Dario; Germano, Serena; Busacca, Sara; Pinato, Sabrina; Tassi, Giancarlo; Favoni, Roberto; Gaudino, Giovanni; Mutti, Luciano
PUB. DATE
August 2007
SOURCE
Thorax;Aug2007, Vol. 62 Issue 8, p690
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr-abl, c-Kit, c-Fms and platelet derived growth factor receptor β (PDGFRβ). PDGFRβ is often overexpressed in mesothelioma cells and is a therapeutic target for imatinib in some solid tumours. A study was undertaken to assess whether imatinib alone or combined with chemotherapeutic agents may be effective for treating mesothelioma. Methods: Cultures from mesothelioma MMP, REN and ISTMES2 cell lines were treated with imatinib alone or in combination with a chemotherapeutic agent. Results: Imatinib induced cytotoxicisy and apoptosis selectively on PDGFRβ positive mesothelioma cells via blockade of receptor phosphorylation and interference with the Akt pathway. Of the chemotherapeutic agents tested in combination with imatinib, a synergistic effect was obtained with gemcitabine and pemetrexed. Conclusions: This study provides a rationale for a novel translational approach to the treatment of mesothelioma which relies on enhancement of tumour chemosensitivity by inhibition of Akt.
ACCESSION #
26359986

 

Related Articles

  • Terapia biológica en cáncer: nuevos tiempos con una visión optimista. Castro, Januario E.; Sandoval, Jose D. // MedUNAB;sep2008, Vol. 11 Issue 2, p73 

    No abstract available.

  • β-Carotene and Retinol Efficacy Trial Follow-Up.  // JNCI: Journal of the National Cancer Institute;12/1/2004, Vol. 96 Issue 23, p1727 

    Reports on the result of the B-carotene and retinol efficacy trial for cancer treatment. Safety profile; Underlying mechanism of action; Response rate achieved by the treatment.

  • Successful Peripheral Blood Stem Cells Collection in Imatinib Pretreated and Nilotinib-Treated ChronicMyeloid Leukemia Patient. Vokurka, Samuel; Koza, Vladimir; Lysak, Daniel; Karas, Michal; Dvorak, Pavel; Jindra, Pavel; Hrabetova, Marcela; Vozobulova, Vera // Journal of Oncology;2010, p1 

    We report a case of a successful mobilization and harvest of the peripheral blood stem cells (PBSCs) in imatinib-pretreated and nilotinib treated 52-year-old woman diagnosed with Philadelphia chromosome-positive and BCR-ABL (b2a2) positive chronic phase CML in 2/2002. She failed interferon-alfa...

  • Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells. Sako, Hiroyuki; Fukuda, Kazumasa; Saikawa, Yoshiro; Nakamura, Rieko; Takahashi, Tsunehiro; Wada, Norihito; Kawakubo, Hirohumi; Takeuchi, Hiroya; Ohmori, Tai; Kitagawa, Yuko // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Despite the benefits of imatinib for treating gastrointestinal stromal tumors (GIST), the prognosis for high risk GIST and imatinib-resistant (IR) GIST remains poor. The mechanisms of imatinib resistance have not yet been fully clarified. The aim of the study was to establish imatinib-resistant...

  • Nursing Implications of Imatinib as Molecularly Targeted Therapy for Gastrointestinal Stromal Tumors. Griffin, Jeanne M.; Amand, Mya St.; Demetri, George D. // Clinical Journal of Oncology Nursing;Apr2005, Vol. 9 Issue 2, p161 

    Gastrointestinal stromal tumor (GIST), a form of soft-tissue sarcoma, is the most common noncarcinomatous tumor of the gastrointestinal tract. Despite its high incidence of recurrence, the malignant potential of GIST has been underrecognized. Advances in diagnostic technology since 2000 have led...

  • UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Singer, J. B.; Shou, Y.; Giles, F.; Kantarjian, H. M.; Hsu, Y.; Robeva, A. S.; Rae, P.; Weitzman, A.; Meyer, J. M.; Dugan, M.; Ottmann, O. G. // Leukemia (08876924);Nov2007, Vol. 21 Issue 11, p2311 

    Nilotinib is a novel BCR-ABL inhibitor with significantly improved potency and selectivity over imatinib. In Phase I and Phase II clinical studies of nilotinib in patients with a variety of leukemias, infrequent instances of reversible, benign elevation of bilirubin were observed. Uridine...

  • Predictive Markers for Haematological Toxicity of Pemetrexed. Kao, S. C. H.; Phan, V. H.; Clarke, S. J. // Current Drug Targets;Jan2010, Vol. 11 Issue 1, p48 

    No abstract available.

  • Impact of relatively new chemotherapeutic agents on the outcome of Egyptian patients with advanced malignant pleural mesothelioma. Gaafar, R; Khaled, H; Sallam, Y.A.; Shafik, H; Aboulkassem, F.A.; Emara, M // Forum of Clinical Oncology;2014, Vol. 5 Issue 1, p29 

    Purpose: Patients with malignant pleural mesothelioma (MPM) are well known to have poor response to chemotherapy. The aim of this work was to evaluate the efficacy and safety of new chemotherapeutic agents for the treatment of Egyptian MPM patients. Patients and methods: The first study was a...

  • Fresh from the pipeline: Pemetrexed disodium. Muhsin, Mohamed; Gricks, Clair; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Oct2004, Vol. 3 Issue 10, p825 

    In February 2004, pemetrexed disodium (Alimta; Eli Lilly), an anticancer drug that targets folate-dependent reactions that are essential for cell proliferation, became the first drug to be approved by the FDA for the treatment of the rare cancer malignant pleural mesothelioma. Its accelerated...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics